Literature DB >> 20061826

High level expression of functional human IgMs in human PER.C6 cells.

Anna Tchoudakova1, Frank Hensel, Alec Murillo, Bernie Eng, Marketa Foley, Lakee Smith, Frank Schoenen, Antonia Hildebrand, Arndt-René Kelter, Leodevico L Ilag, H Peter Vollmers, Stephanie Brandlein, Jane McIninch, John Chon, Gene Lee, Marco Cacciuttolo.   

Abstract

Natural IgM antibodies play an important role in the body's defense mechanisms against transformed cells in the human body and are currently being exploited both in prognoses of malignant lesions and in the therapy of cancer patients. However, despite growing interest and clinical promise, thus far the IgM class of antibodies has failed to gain widespread commercial interest as these are considered to be difficult to produce recombinantly. IgMs are polymeric and have a relatively large mass. In addition, IgM molecules are heavily glycosylated and, when produced in non-human cell lines, they may contain non-human glycan structures which may be potentially immunogenic. Clearly, production systems capable of expressing human recombinant IgM antibodies are needed. We have successfully used PER.C6 cells-a human cell line-to generate three separate human recombinant monoclonal IgMs in suspension cultures in protein-free medium. All three of the IgMs were constructed with joining (J) chain and were expressed in the pentameric form. One of the IgMs was also expressed as a hexamer without J chain. Clones with cell specific productivities greater than 20 pg/cell/day were generated, which led to yields of 0.5 g/L to 2g/L in fed-batch production. All the IgMs expressed were biologically active as shown in binding and cytotoxicity assays. These studies demonstrate the potential of PER.C6 cells for the production of high levels of functional recombinant IgM and other polymeric molecules, using a straightforward and rapid stable cell line generation method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20061826      PMCID: PMC2725415          DOI: 10.4161/mabs.1.2.7945

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  23 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  High-level expression of recombinant IgG in the human cell line per.c6.

Authors:  David Jones; Nathalie Kroos; Regina Anema; Bart van Montfort; Andre Vooys; Sven van der Kraats; Esmeralda van der Helm; Shirley Smits; Jan Schouten; Kirsten Brouwer; Fija Lagerwerf; Patrick van Berkel; Dirk-Jan Opstelten; Ton Logtenberg; Abraham Bout
Journal:  Biotechnol Prog       Date:  2003 Jan-Feb

Review 3.  Natural antibodies and cancer.

Authors:  H Peter Vollmers; Stephanie Brändlein
Journal:  J Autoimmun       Date:  2007-09-12       Impact factor: 7.094

4.  Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.

Authors:  Reiko F Irie; David W Ollila; Steven O'Day; Donald L Morton
Journal:  Cancer Immunol Immunother       Date:  2003-10-16       Impact factor: 6.968

5.  Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients.

Authors:  Stephanie Brändlein; Judith Lorenz; Nele Ruoff; Frank Hensel; Ines Beyer; Justus Müller; Konrad Neukam; Bertram Illert; Matthias Eck; Hans Konrad Müller-Hermelink; H Peter Vollmers
Journal:  Hum Antibodies       Date:  2002

6.  Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans.

Authors:  Stephanie Brändlein; Tina Pohle; Nele Ruoff; Ewa Wozniak; Hans-Konrad Müller-Hermelink; H Peter Vollmers
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

7.  Differential activation of human and guinea pig complement by pentameric and hexameric IgM.

Authors:  Cathy Collins; Florence W L Tsui; Marc J Shulman
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

8.  Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen.

Authors:  P C Jones; L L Sze; P Y Liu; D L Morton; R F Irie
Journal:  J Natl Cancer Inst       Date:  1981-02       Impact factor: 13.506

Review 9.  Natural IgM antibodies, the ignored weapons in tumour immunity.

Authors:  S Brändlein; H P Vollmers
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

Review 10.  The making of a professional secretory cell: architectural and functional changes in the ER during B lymphocyte plasma cell differentiation.

Authors:  Luigina Tagliavacca; Tiziana Anelli; Claudio Fagioli; Alexandre Mezghrani; Elena Ruffato; Roberto Sitia
Journal:  Biol Chem       Date:  2003-09       Impact factor: 3.915

View more
  21 in total

1.  Designed IgM from glycoengineering.

Authors:  Andrew Hiatt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-15       Impact factor: 11.205

2.  Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.

Authors:  Bérengère Vire; Martin Skarzynski; Joshua D Thomas; Christopher G Nelson; Alexandre David; Georg Aue; Terrence R Burke; Christoph Rader; Adrian Wiestner
Journal:  Cancer Res       Date:  2014-10-24       Impact factor: 12.701

3.  Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.

Authors:  Yabing Cao; Yongsheng Lan; Jianfei Qian; Yuhuan Zheng; Sungyoul Hong; Haiyan Li; Michael Wang; Larry W Kwak; Dongyu Lin; Jing Yang; Qing Yi
Journal:  Br J Haematol       Date:  2011-05-09       Impact factor: 6.998

4.  IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.

Authors:  Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

5.  A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1.

Authors:  Lisette A H M Cornelissen; Robert P de Vries; Els A de Boer-Luijtze; Alan Rigter; Peter J M Rottier; Cornelis A M de Haan
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

6.  TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Authors:  Xiuhong Piao; Tatsuhiko Ozawa; Hiroshi Hamana; Kiyomi Shitaoka; Aishun Jin; Hiroyuki Kishi; Atsushi Muraguchi
Journal:  Oncoimmunology       Date:  2016-05-04       Impact factor: 8.110

7.  Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM.

Authors:  Edward S X Moh; Chi-Hung Lin; Morten Thaysen-Andersen; Nicolle H Packer
Journal:  J Am Soc Mass Spectrom       Date:  2016-04-01       Impact factor: 3.109

8.  Expression and glycoengineering of functionally active heteromultimeric IgM in plants.

Authors:  Andreas Loos; Clemens Gruber; Friedrich Altmann; Ulrich Mehofer; Frank Hensel; Melanie Grandits; Chris Oostenbrink; Gerhard Stadlmayr; Paul G Furtmüller; Herta Steinkellner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

9.  The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.

Authors:  Zachary Rosenes; Terrence D Mulhern; Danny M Hatters; Leodevico L Ilag; Barbara E Power; Chris Hosking; Frank Hensel; Geoffrey J Howlett; Yee-Foong Mok
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.

Authors:  Leo Rasche; Johannes Duell; Charlotte Morgner; Manik Chatterjee; Frank Hensel; Andreas Rosenwald; Hermann Einsele; Max S Topp; Stephanie Brändlein
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.